Cancer resistance to chemotherapeutics is a common problem often encountered in the clinical setting, hampering greatly the conventional therapy of malignant diseases for several decades. No generally efficient mechanism solving this phenomenon was found so far. Cancer cells can adapt to a stress applied in the form of chemotherapeutics and become insensitive to their effects. Under such a selection pressure, the cancer cells acquire features helping them not only to survive the changes in the environment but also to further divide and to form secondary lesions. Therefore, besides developing novel chemotherapeutics, refining the drug delivery mechanisms of the conventional ones is absolutely crucial to defeat the cancer, so we can fully benefit from the effects these therapeutics offer. Here, we demonstrated enhanced delivery of doxorubicin (DOX) to a DOX-resistant ovarian cancer cell line using completely novel 2D material 4-carboxybutylgermanane (Ge-Bu-COOH). In our study, we present Ge-Bu-COOH as a drug carrier evincing high drug-loading efficiency, low cytotoxicity up to the concentration of 2.5 μg/mL and no hemolysis. Simultaneously, binding DOX to Ge-Bu-COOH increases DOX accumulation in the DOX-resistant cell lines. It leads to a significant anticancer efficiency enhancement in A2780/ADR DOX-resistant cell line; with the maximal effect reaching up to 62.8% compared to free DOX. These findings have profound influence on understanding the behaviour of doxorubicin-resistant tumours and open new horizon to manage their treatment.

癌症对化学疗法的抗性是在临床环境中经常遇到的常见问题，几十年来极大地阻碍了传统的恶性疾病治疗。到目前为止，尚未找到解决该现象的普遍有效的机制。癌细胞可以适应以化学疗法形式施加的压力，并且对其作用不敏感。在这样的选择压力下，癌细胞获得的特征不仅可以帮助它们在环境变化中生存，还可以进一步分裂并形成继发性病变。因此，除了开发新的化学疗法之外，完善常规药物的给药机制对于抵抗癌症绝对至关重要，因此我们可以充分受益于这些疗法的作用。这里，我们证明了使用完全新颖的2D材料4-羧丁基锗烷（Ge-Bu-COOH）将阿霉素（DOX）增强递送至抗DOX的卵巢癌细胞系。在我们的研究中，我们提出了Ge-Bu-COOH作为药物载体，显示出高载药效率，低至2.5μg/ mL浓度的低细胞毒性和无溶血作用。同时，将DOX与Ge-Bu-COOH结合会增加DOX耐药细胞系中DOX的积累。它可显着提高A2780 / ADR DOX耐药细胞系的抗癌效率；与免费DOX相比，最大效果达到62.8％。这些发现对理解对阿霉素耐药的肿瘤的行为具有深远的影响，并为治疗其开辟了新的视野。